Challenges and progress in research, diagnostics, and therapeutics in Alzheimer's disease and related dementias.

Autor: Dokholyan NV; Departments of Pharmacology Penn State College of Medicine Hershey Pennsylvania USA.; Departments of Biochemistry & Molecular Biology Penn State College of Medicine Hershey Pennsylvania USA., Mohs RC; Global Alzheimer's Platform Foundation Washington DC USA., Bateman RJ; Department of Neurology Washington University School of Medicine St. Louis Missouri USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2022 Jul 26; Vol. 8 (1), pp. e12330. Date of Electronic Publication: 2022 Jul 26 (Print Publication: 2022).
DOI: 10.1002/trc2.12330
Abstrakt: The health, well-being, and financial security of Americans are greatly impacted by Alzheimer's disease. The forecast paints an upward trajectory with the number of Americans suffering from Alzheimer's disease and related dementia. To discuss the Alzheimer's crisis, The Senate Committee on Finance, Subcommittee on Health Care, held a hearing titled, "The Alzheimer's Crisis: Examining, Testing, and Treatment Pipelines and Fiscal Implications," on December 16, 2020. Here, we summarize and expand on the discussion of the panel and its review of recent progress, ongoing challenges associated with Alzheimer's disease, and potential initiatives that promise to speed progress in developing treatments and improving care.
Competing Interests: N.V.D. is the President of the Molecules in Action LLC. He also serves on the advisory board at Atom Bioworks. He also serves as the Editor‐in‐Chief of Proteins. R.C.M. is the Chief Science Officer for the Global Alzheimer's Platform (GAP) Foundation and Vice President for Clinical Development at Agenebio, Inc. a Baltimore‐based biotechnology company; he is PI for NIA Grant R01AG061091 “A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease” awarded to AgeneBio. He is member of the Board of Governors for the Alzheimer's Drug Discovery Foundation (ADDF), and a member of the Board of Directors for CogState, Ltd. He has received consulting fees from Vaxxinity, Inc., Amyriad Therapeutics, and the MD Anderson Cancer Center, Center for Neurodegeneration. R.J.B. has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. Washington University and RJB have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. R.J.B. has received honoraria as a speaker, consultant, or advisory board member from Amgen and Roche.
(© 2022 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: